PE20160529A1 - Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas - Google Patents
Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativasInfo
- Publication number
- PE20160529A1 PE20160529A1 PE2016000076A PE2016000076A PE20160529A1 PE 20160529 A1 PE20160529 A1 PE 20160529A1 PE 2016000076 A PE2016000076 A PE 2016000076A PE 2016000076 A PE2016000076 A PE 2016000076A PE 20160529 A1 PE20160529 A1 PE 20160529A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- treatment
- combination
- hyperproliferative diseases
- gdc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La invencion proporciona combinaciones que comprenden un inhibidor de MEK tal como GDC-0973, GDC-0623, GSK-112 0212 (trametinib), AZD-6244 (selumetinib), etc; o una de sus sales farmaceuticamente aceptables y un inhibidor de ERK (tal como GDC-0994, [(S)-1-(1-(4-cloro-3-fluorofenil)-2-hidroxietil)-4-(2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)piridin-2(1H)-ona]. Las combinaciones son particularmente utiles para tratar trastornos hiperproliferativos, tal como el cancer
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361874206P | 2013-09-05 | 2013-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20160529A1 true PE20160529A1 (es) | 2016-05-21 |
Family
ID=51492945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000076A PE20160529A1 (es) | 2013-09-05 | 2014-09-04 | Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas |
Country Status (21)
Country | Link |
---|---|
US (1) | US9532987B2 (es) |
EP (1) | EP3041471A1 (es) |
JP (2) | JP2016531139A (es) |
KR (1) | KR20160048807A (es) |
CN (1) | CN105517548B (es) |
AR (1) | AR097556A1 (es) |
AU (1) | AU2014317119B2 (es) |
CA (1) | CA2916619A1 (es) |
CL (1) | CL2016000042A1 (es) |
EA (1) | EA034872B1 (es) |
HK (1) | HK1218072A1 (es) |
IL (1) | IL243251B (es) |
MA (1) | MA38827A1 (es) |
MX (1) | MX370417B (es) |
PE (1) | PE20160529A1 (es) |
PH (1) | PH12016500270A1 (es) |
SG (1) | SG11201600989VA (es) |
TW (1) | TW201605477A (es) |
UA (1) | UA120423C2 (es) |
WO (1) | WO2015032840A1 (es) |
ZA (1) | ZA201600091B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013130976A1 (en) * | 2012-03-01 | 2013-09-06 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
UA120506C2 (uk) | 2013-12-06 | 2019-12-26 | Дженентек, Інк. | Інгібітори серин/треонінкіназ |
KR102396710B1 (ko) * | 2013-12-30 | 2022-05-10 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 저해제 |
WO2016162325A1 (en) | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
SI3374359T1 (sl) | 2015-11-09 | 2020-04-30 | Astrazeneca Ab | Derivati dihidroimidazopirazinona uporabni pri zdravljenju raka |
WO2017080980A1 (en) | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
CN105330643B (zh) * | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
KR20180134347A (ko) * | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
WO2018039211A1 (en) * | 2016-08-23 | 2018-03-01 | Genentech, Inc. | Combination therapy for the treatment of pancreatic cancer |
MY194462A (en) * | 2016-11-25 | 2022-11-30 | Genuv Inc | Composition for Promoting Differentiation of and Protecting Neural Stem Cells and Method for Inducing Neural Regeneration using same |
JP2019019094A (ja) * | 2017-07-19 | 2019-02-07 | 学校法人福岡大学 | 変異kras関連シグナル阻害用組成物 |
JP2020532982A (ja) | 2017-09-08 | 2020-11-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの診断及び治療方法 |
WO2019139970A1 (en) * | 2018-01-09 | 2019-07-18 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
WO2021007499A1 (en) * | 2019-07-11 | 2021-01-14 | Emory University | Combination therapies for managing cancer |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1934174B1 (en) * | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
US20080085886A1 (en) | 2006-08-21 | 2008-04-10 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
BRPI0714629A2 (pt) | 2006-08-21 | 2013-05-07 | Genentech Inc | composto, composiÇço farmacÊutica, mÉtodo para inibir o crescimento celular, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para trataruma doenÇa auto-imune, lesço àsseo destrutiva, distérbios proliferativos, doenÇas infecciosas, doenÇas virais, doenÇas fibràticas ou doenÇas neurodegenerativas |
PE20081354A1 (es) | 2006-11-30 | 2008-11-14 | Genentech Inc | Compuestos de azaindolilo como inhibidores de mek |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
WO2008157179A2 (en) | 2007-06-12 | 2008-12-24 | Genentech, Inc. | N-substituted azaindoles and methods of use |
PL2222675T3 (pl) | 2007-12-19 | 2014-02-28 | Genentech Inc | 5-anilinoimidazopirydyny i sposoby zastosowania |
EP2231662B1 (en) | 2007-12-19 | 2011-06-22 | Genentech, Inc. | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
JP5710269B2 (ja) | 2007-12-21 | 2015-04-30 | ジェネンテック, インコーポレイテッド | アザインドリジン類と使用方法 |
WO2010003025A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Bicyclic heterocycles as mek kinase inhibitors |
CN102137843A (zh) | 2008-07-01 | 2011-07-27 | 健泰科生物技术公司 | 作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法 |
EP2470898A4 (en) | 2009-08-24 | 2013-03-13 | Genentech Inc | DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT IN DETECTION OF K-RAS MUTATIONS AND MEASURING RTK EXPRESSION LEVELS |
TWI428336B (zh) | 2009-10-12 | 2014-03-01 | Hoffmann La Roche | Pi3k抑制劑及mek抑制劑之組合 |
SG190361A1 (en) | 2010-11-23 | 2013-06-28 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
BR112014002675A2 (pt) | 2011-08-04 | 2017-02-21 | Array Biopharma Inc | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" |
WO2013130976A1 (en) | 2012-03-01 | 2013-09-06 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
KR20150023318A (ko) | 2012-05-30 | 2015-03-05 | 에프. 호프만-라 로슈 아게 | 피롤리디노 헤테로사이클 |
MX367970B (es) | 2012-08-17 | 2019-09-11 | Hoffmann La Roche | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafinib. |
MX369989B (es) | 2012-08-27 | 2019-11-27 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas. |
MX2015004660A (es) | 2012-10-12 | 2015-08-07 | Exelixis Inc | Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer. |
CN104755478B (zh) | 2012-10-16 | 2017-10-10 | 霍夫曼-拉罗奇有限公司 | 丝氨酸/苏氨酸激酶抑制剂 |
UA120506C2 (uk) | 2013-12-06 | 2019-12-26 | Дженентек, Інк. | Інгібітори серин/треонінкіназ |
KR102396710B1 (ko) | 2013-12-30 | 2022-05-10 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 저해제 |
CN105848723B (zh) | 2013-12-30 | 2019-08-02 | 基因泰克公司 | 丝氨酸/苏氨酸激酶抑制剂 |
EP3129025B1 (en) | 2014-04-09 | 2019-05-15 | Genentech, Inc. | Process for the manufacturing of medicaments |
-
2014
- 2014-08-29 US US14/473,311 patent/US9532987B2/en not_active Expired - Fee Related
- 2014-09-04 WO PCT/EP2014/068776 patent/WO2015032840A1/en active Application Filing
- 2014-09-04 TW TW103130648A patent/TW201605477A/zh unknown
- 2014-09-04 CN CN201480048950.XA patent/CN105517548B/zh not_active Expired - Fee Related
- 2014-09-04 KR KR1020167005716A patent/KR20160048807A/ko not_active Application Discontinuation
- 2014-09-04 CA CA2916619A patent/CA2916619A1/en not_active Abandoned
- 2014-09-04 MX MX2016002857A patent/MX370417B/es active IP Right Grant
- 2014-09-04 EA EA201690513A patent/EA034872B1/ru not_active IP Right Cessation
- 2014-09-04 PE PE2016000076A patent/PE20160529A1/es unknown
- 2014-09-04 AR ARP140103309A patent/AR097556A1/es unknown
- 2014-09-04 JP JP2016539537A patent/JP2016531139A/ja not_active Withdrawn
- 2014-09-04 MA MA38827A patent/MA38827A1/fr unknown
- 2014-09-04 EP EP14761328.5A patent/EP3041471A1/en not_active Withdrawn
- 2014-09-04 SG SG11201600989VA patent/SG11201600989VA/en unknown
- 2014-09-04 UA UAA201603616A patent/UA120423C2/uk unknown
- 2014-09-04 AU AU2014317119A patent/AU2014317119B2/en not_active Expired - Fee Related
-
2015
- 2015-12-21 IL IL243251A patent/IL243251B/en not_active IP Right Cessation
-
2016
- 2016-01-06 ZA ZA2016/00091A patent/ZA201600091B/en unknown
- 2016-01-08 CL CL2016000042A patent/CL2016000042A1/es unknown
- 2016-02-09 PH PH12016500270A patent/PH12016500270A1/en unknown
- 2016-05-30 HK HK16106100.6A patent/HK1218072A1/zh unknown
-
2018
- 2018-10-03 JP JP2018188348A patent/JP2019031517A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11201600989VA (en) | 2016-03-30 |
JP2016531139A (ja) | 2016-10-06 |
JP2019031517A (ja) | 2019-02-28 |
US9532987B2 (en) | 2017-01-03 |
HK1218072A1 (zh) | 2017-02-03 |
AR097556A1 (es) | 2016-03-23 |
MA38827A1 (fr) | 2017-10-31 |
EA201690513A1 (ru) | 2016-07-29 |
WO2015032840A1 (en) | 2015-03-12 |
ZA201600091B (en) | 2017-04-26 |
MX370417B (es) | 2019-12-10 |
AU2014317119B2 (en) | 2019-12-05 |
CL2016000042A1 (es) | 2016-08-05 |
CA2916619A1 (en) | 2015-03-12 |
TW201605477A (zh) | 2016-02-16 |
CN105517548B (zh) | 2020-01-21 |
KR20160048807A (ko) | 2016-05-04 |
MX2016002857A (es) | 2016-06-22 |
US20150111869A1 (en) | 2015-04-23 |
EA034872B1 (ru) | 2020-03-31 |
CN105517548A (zh) | 2016-04-20 |
EP3041471A1 (en) | 2016-07-13 |
AU2014317119A1 (en) | 2016-03-03 |
UA120423C2 (uk) | 2019-12-10 |
PH12016500270A1 (en) | 2016-05-16 |
IL243251B (en) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20160529A1 (es) | Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas | |
CL2017001566A1 (es) | Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales. | |
CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
CY1122279T1 (el) | Ενωσεις ναφθυριδινης αναστολεις κινασης jak | |
MX2019007256A (es) | Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano. | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
CR20160036A (es) | Inhibidores cristalinos de bromodominios | |
MY196243A (en) | Dihydropyrimidine Compounds and Their Application In Pharmaceuticals | |
BR112017024917A2 (pt) | síntese de compostos heterocíclicos | |
MX2017013797A (es) | Inhibidor de janus quinasa. | |
CU24419B1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas | |
UY37205A (es) | Inhibidores de bromodominios | |
EA202192151A1 (ru) | Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k | |
AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
CY1121806T1 (el) | Ιμιδαζοπυραζινονες ως αναστολεις pde1 | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
UY36713A (es) | Triazoles para el tratamiento de enfermedades desmielinizantes | |
AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
MX2014013855A (es) | Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales. | |
TW201625535A (en) | Inhibitors of histone demethylases | |
EP3492468A4 (en) | HETEROCYCLIC COMPOUND AS A JAK INHIBITOR, SALTS AND THERAPEUTIC USE THEREOF | |
CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
CY1122587T1 (el) | 1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4η-πυρρολο[3,2-d]πυριμιδιν-4-ονες ως αναστολεις της μυελοϋπεροξειδασης |